Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors  

作　　者：Bansi P Savaliya Ramin Shekouhi Fatima Mubarak Harsheen K Manaise Paola Berrios Jimenez Gabrielle Kowkabany Reed A Popp Kyle Popp Emmanuel Gabriel 

机构地区：[1]Department of Surgery,Medical Academy Named after SI Georgievsky of Vernadsky Crimean Federal University,Simferopol 295015,Crimea,Russia [2]Division of Plastic and Reconstructive Surgery,Department of Surgery,University of Florida,Gainesville,FL 32608,United States [3]Department of Surgery,Aga Khan University,Karachi 74800,Sindh,Pakistan [4]Department of Surgery,Government Medical College and Hospital,Chandigarh 160030,Punjab,India [5]Department of Surgery,University of Puerto Rico School of Medicine,San Juan 00921,Puerto Rico [6]Department of Chemical and Biological Engineering,University of Alabama,Tuscaloosa,AL 35487,United States [7]Department of Surgery,University of Florida College of Medicine,Gainesville,FL 32610,United States [8]Department of Surgery,Florida State University,Tallahassee,FL 32306,United States [9]Department of Surgery,Mayo Clinic,Jacksonville,FL 32224,United States

出　　处：《World Journal of Gastroenterology》2024年第24期3052-3058,共7页世界胃肠病学杂志（英文版）

摘　　要：This editorial commented on an article in the World Journal of Gastroenterology titled“Risks of Reactivation of Hepatitis B Virus in Oncological Patients Using Tyrosine Kinase-Inhibitors:Case Report and Literature Analysis”by Colapietro et al.In this editorial,we focused on providing a more comprehensive exploration of hepatitis B virus reactivation(HBVr)associated with the usage of tyrosine kinase inhibitors(TKIs).It includes insights into the mechanisms underlying HBV reactivation,the temporal relationship between TKIs and HBV reactivation,and preventive measures.The aim is to understand the need for nucleos(t)ide analogs(NAT)and serial blood tests for early recognition of reactivation and acute liver injury,along with management strategies.TKIs are considered to be an intermediate(1%-10%)of HBVr.Current guidelines stipulate that patients receiving therapy with high or moderate risks of reactivation or recent cancer diagnosis must have at least tested hepatitis B surface antigen,anti-hepatitis B core antigen(HBc),and anti-hepatitis B surface antibody.Anti-HBc screening in highly endemic areas means people with negative tests should be vaccinated against HBV.Nucleoside or nucleotide analogs(NAs)like entecavir(ETV),tenofovir disoproxil fumarate(TDF),and tenofovir alafenamide(TAF)form the basis of HBV reactivation prophylaxis and treatment during immunosuppression.Conversely,lamivudine,telbivudine,and adefovir are generally discouraged due to their reduced antiviral efficacy and higher risk of fostering drug-resistant viral strains.However,these less effective NAs may still be utilized in cases where ETV,TDF,and TAF are not feasible treatment options.

关 键 词：Hepatitis B virus REACTIVATION Chronic hepatitis B Tyrosine-kinase inhibitor IMMUNOMODULATORS IMMUNOSUPPRESSANT Nucleoside analogue Hemato-oncology 

分 类 号：R512.62[医药卫生—内科学]